Floatz logo

AZD1775

Ovarian Serous Surface Papillary Adenocarcinoma

National Cancer Institute (NCI)Phase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Ovarian Serous Surface Papillary Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2B
Everolimus
Mayo Clinic
Phase 2B
Letrozole
Mayo Clinic
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Olaparib
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

AZD1775 is also rated in:

refractory malignant neoplasmDormant
B
Indicative ·
62 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
B
Indicative ·
60 / 100
View asset →
exocrine pancreatic carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →